| 000 | 01637 a2200469 4500 | ||
|---|---|---|---|
| 005 | 20250515033609.0 | ||
| 264 | 0 | _c20061128 | |
| 008 | 200611s 0 0 eng d | ||
| 022 | _a0954-6928 | ||
| 024 | 7 |
_a10.1097/00019501-200608000-00010 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aZhao, Jing-lin | |
| 245 | 0 | 0 |
_aPretreatment with fosinopril or valsartan reduces myocardial no-reflow after acute myocardial infarction and reperfusion. _h[electronic resource] |
| 260 |
_bCoronary artery disease _cAug 2006 |
||
| 300 |
_a463-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Research Support, Non-U.S. Gov't | ||
| 650 | 0 | 4 | _aAcute Disease |
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntihypertensive Agents _xpharmacology |
| 650 | 0 | 4 |
_aBlood Flow Velocity _xdrug effects |
| 650 | 0 | 4 | _aChemoprevention |
| 650 | 0 | 4 |
_aEndothelium _xdrug effects |
| 650 | 0 | 4 |
_aFosinopril _xpharmacology |
| 650 | 0 | 4 |
_aH(+)-K(+)-Exchanging ATPase _xdrug effects |
| 650 | 0 | 4 | _aModels, Animal |
| 650 | 0 | 4 |
_aMyocardial Infarction _xprevention & control |
| 650 | 0 | 4 | _aMyocardial Reperfusion |
| 650 | 0 | 4 | _aMyocardium |
| 650 | 0 | 4 | _aSwine |
| 650 | 0 | 4 |
_aTetrazoles _xpharmacology |
| 650 | 0 | 4 | _aTime Factors |
| 650 | 0 | 4 |
_aValine _xanalogs & derivatives |
| 650 | 0 | 4 | _aValsartan |
| 700 | 1 | _aYang, Yue-jin | |
| 700 | 1 | _aYou, Shi-jie | |
| 700 | 1 | _aJing, Zhi-cheng | |
| 700 | 1 | _aWu, Yong-jian | |
| 700 | 1 | _aCheng, Ji-lin | |
| 700 | 1 | _aGao, Run-lin | |
| 773 | 0 |
_tCoronary artery disease _gvol. 17 _gno. 5 _gp. 463-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1097/00019501-200608000-00010 _zAvailable from publisher's website |
| 999 |
_c16435879 _d16435879 |
||